Janux Therapeutics Inc.
JANX | NASDAQ
$17.34
+$0.33 (+1.94%)
Sep 22, 2026, 11:25 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 10M | 10.59M | 8.08M | 8.61M | 3.64M | n/a |
Cost of Revenue | 2.03M | 2.06M | 1.96M | 841K | 26.24M | 13K |
Gross Profit | 7.97M | 8.53M | 6.13M | 7.77M | -22.6M | -13K |
Operating Income | -157.67M | -98.85M | -72.98M | -67.09M | -32.93M | -4.84M |
Interest Income | 44.04M | 29.85M | 14.69M | 4.03M | 257K | 206K |
Pretax Income | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M | -6.78M |
Net Income | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M | -6.78M |
Selling & General & Admin | 41.77M | 41.05M | 26.14M | 22.26M | 10.33M | 1.79M |
Research & Development | 125.9M | 68.39M | 54.92M | 53.44M | 26.24M | 3.04M |
Other Expenses | -2.03M | -2.06M | -1.96M | -841K | -26.24M | n/a |
Operating Expenses | 165.64M | 107.38M | 79.11M | 74.86M | 10.33M | 4.83M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 206K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 167.67M | 109.44M | 81.06M | 75.7M | 36.57M | 4.84M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 61.97M | 53.75M | 44.02M | 41.47M | 41.24M | 41.61M |
Shares Outstanding (Diluted) | 61.97M | 53.75M | 44.02M | 41.47M | 41.24M | 41.61M |
EPS (Basic) | -1.83 | -1.28 | -1.32 | -1.52 | -0.79 | -0.16 |
EPS (Diluted) | -1.83 | -1.28 | -1.32 | -1.52 | -0.79 | -0.16 |
EBITDA | -111.6M | -66.93M | -56.34M | -62.22M | -32.56M | -6.57M |
EBIT | -113.63M | -68.99M | -58.29M | -63.06M | -32.67M | -6.58M |
Depreciation & Amortization | 2.03M | 2.06M | 1.96M | 841K | 113K | 13K |
Add to Watchlist
Select watchlists to add or remove JANX